Cancer Family
Papillary Epithelial Neoplasm
CI-CAN-00000311Explore in graph →
Non-malignant70 active trials23 evidence items
- NCIt
- C8429
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000311Explore in graph →
Clinical trials
281 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07630363 | PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC | not yet recruiting | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03257761 | Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer | active not recruiting | Phase 1 | 55 | University of Southern CaliforniaOTHER | 1 | Jun 1, 2026 |
| clinicaltrials |
| NCT07584447 | Clinical Utility of Preoperative Thyroid GuidePx® Testing | not yet recruiting | — | 85 | University of CalgaryOTHER | 0 | Jun 1, 2026 | clinicaltrials |
| NCT05043090 | Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC(SAMETA) | active not recruiting | Phase 3 | 148 | AstraZenecaINDUSTRY | 25 | May 22, 2026 | clinicaltrials |
| NCT04759911 | Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07376837 | Radiofrequency Ablation for Curative Treatment of Small Low-Risk Papillary Thyroid Cancer: Pilot Study(PTC-RFA) | recruiting | N/A | 30 | University Health Network, TorontoOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT00898365 | Study of Kidney Tumors in Younger Patients | completed | — | 8,000 | Children's Oncology GroupNETWORK | 7 | May 18, 2026 | clinicaltrials |
| NCT02609685 | Active Surveillance of Papillary Thyroid Microcarcinoma(PMCAS) | recruiting | N/A | 216 | Cedars-Sinai Medical CenterOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06730321 | Surgical Competency for Robot-Assisted Thyroidectomy: Construction and Validation of a Robotic Thyroidectomy Assessment Score (RTAS) | recruiting | — | 200 | Shanghai 6th People's HospitalOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06899347 | The Role of Prophylactic Central Compartment Neck Dissection in the Management of 2 to 4 cm Papillary Thyroid Carcinoma(PRO-COMAND) | not yet recruiting | N/A | 392 | Leonardo RossiOTHER | 0 | May 5, 2026 | clinicaltrials |
| NCT02495896 | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 61 | University of Southern CaliforniaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07556835 | Outcomes After Liver and Biliary Resection at a High-Volume Center(BILIVER) | not yet recruiting | — | 1,000 | Azienda USL Toscana CentroOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07536412 | Decision Aid Efficacy in Low Risk Thyroid Cancer | not yet recruiting | N/A | 34 | University of Maryland, BaltimoreOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04948437 | Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer | active not recruiting | — | 103 | National Taiwan University HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06316895 | The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma | recruiting | — | 3,772 | Chinese PLA General HospitalOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT03753919 | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial(DUTHY) | terminated | Phase 2 | 79 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT03868475 | Comparing Vacuum-Assisted Percutaneous Excision to Open Surgical Excision for Borderline or High-Risk Breast Lesions(VAPEX) | withdrawn | N/A | 0 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 0 | Mar 9, 2026 | clinicaltrials |
| NCT05122546 | CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | active not recruiting | Phase 1 | 31 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07243067 | Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer | not yet recruiting | — | 300 | Mayo ClinicOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04430738 | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | active not recruiting | Phase 2 | 40 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | Feb 24, 2026 | clinicaltrials |
| NCT07391514 | Deep Learning-Based Intraoperative Dual-tracer Video Analysis of Sentinel Lymph Node Mapping for Metastasis Prediction in cN0 Papillary Thyroid Carcinoma | completed | — | 131 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06235814 | Molecular Analysis for Precision Surgery in Thyroid Cancer Trial(MAPS) | completed | N/A | 2 | University of California, Los AngelesOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06440850 | Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation | recruiting | Phase 2 | 21 | City of Hope Medical CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04623502 | An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy | recruiting | N/A | 600 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05014698 | IDEntification of New Predisposition Genes in Differentiated THYroid Cancer(IDENTHY-K) | terminated | N/A | 34 | Nantes University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07357571 | Preoperative Prediction of Lymph Node Metastasis in T1N0M0 Papillary Thyroid Carcinoma by Using Contrast-enhanced Ultrasound | recruiting | — | 600 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07354698 | Application of Mitoxantrone Hydrochloride Injection in Transoral Robotic Thyroid Cancer Surgery(MHI) | not yet recruiting | Phase 4 | 114 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06133374 | Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples | recruiting | — | 130 | University of CalgaryOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT03768414 | Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers | completed | Phase 3 | 452 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05194072 | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | terminated | Phase 1 | 250 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 5 | Jan 9, 2026 | clinicaltrials |
| NCT03899792 | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors(LIBRETTO-121) | active not recruiting | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 11 | Jan 6, 2026 | clinicaltrials |
| NCT07314255 | The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma(ZL2025) | active not recruiting | — | 60 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06715839 | Target-specific immunoPET Imaging of Digestive System Carcinoma | recruiting | N/A | 400 | RenJi HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07299318 | Multimodal Deep Learning for Lymph Node Metastasis in Thyroid Cancer | not yet recruiting | — | 3,200 | West China HospitalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06623578 | Comparative Study of Transaxillary Robotic Thyroidectomy With MRND Versus Conventional Open Surgery in N1b PTC | recruiting | N/A | 876 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04624477 | Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer | active not recruiting | — | 450 | University Health Network, TorontoOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05024929 | Targeted Therapy to Increase RAI Uptake in Metastatic DTC | recruiting | — | 32 | Children's Hospital of PhiladelphiaOTHER | 2 | Nov 14, 2025 | clinicaltrials |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | terminated | Phase 2 | 23 | Day One Biopharmaceuticals, Inc.INDUSTRY | 7 | Oct 2, 2025 | clinicaltrials |
| NCT07167329 | Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial(BELIEVE-VHL) | recruiting | Phase 2 | 100 | José Claudio Casali da RochaOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04462471 | Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers | completed | Phase 1 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT04853017 | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors(AMPLIFY-201) | completed | Phase 1 | 25 | Elicio TherapeuticsINDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06439745 | More Than 50% of Unifocal cN0 T1b/Small T2 Papillary Thyroid Carcinoma May Require Completion Thyroidectomy if Nodal Status is Evaluated(cN0PTC) | completed | — | 314 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Sep 2, 2025 | clinicaltrials |
| NCT02973997 | Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) | completed | Phase 2 | 57 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT01723202 | Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer | completed | Phase 2 | 53 | Bhavana KondaOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT05752669 | Oxidative Stress and Mitochondrial TERT in Papillary Thyroid Cancer.(TEMPEST) | completed | — | 100 | Istituto Auxologico ItalianoOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT07107503 | 10 Years' Follow-up Results of Ultrasound-guided Radiofrequency Ablation Versus Surgery for Low-risk Papillary Thyroid Micro-carcinoma | completed | — | 757 | Yi MaoOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT04197960 | Microwave Ablation and Surgical Resection for Micropapillary Thyroid Carcinoma | completed | N/A | 973 | Chinese PLA General HospitalOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT02375880 | Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder | completed | Phase 1 | 51 | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT07066644 | Intraoperative Pathologic Evaluation of Central Lymph Nodes in Papillary Thyroid Carcinoma | completed | — | 509 | Seoul National University HospitalOTHER | 1 | Jul 18, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jun 5, 2026source: clinicaltrials